Vaccine Strain Research Articles

Seasonal antigenic prediction of influenza A H3N2 using machine learning

Antigenic characterization of circulating influenza A virus (IAV) isolates is routinely assessed by using the hemagglutination inhibition (HI) assays for surveillance purposes. It is also used to determine the need for annual influenza vaccine updates as well as for pandemic preparedness. Performing antigenic characterization of IAV on a global scale is confronted with high costs, animal availability, and other practical challenges. Here we present a machine learning model that accurately predicts (normalized) outputs of HI assays involving circulating human IAV H3N2 viruses, using their hemagglutinin subunit 1 (HA1) sequences and associated metadata. Each season, the model learns an updated nonlinear mapping of genetic to antigenic changes using data from past seasons only. The model accurately distinguishes antigenic variants from non-variants and adaptively characterizes seasonal dynamics of HA1 sites having the strongest influence on antigenic change. Antigenic predictions produced by the model can aid influenza surveillance, public health management, and vaccine strain selection activities.

Diagnostic investigation of avian reovirus field variants circulating in broiler chickens in Pennsylvania of United States between 2017 and 2022

ABSTRACT Avian reovirus (ARV) has been continuously affecting the poultry industry in Pennsylvania (PA) in recent years. This report provides our diagnostic investigation on monitoring ARV field variants from broiler chickens in Pennsylvania. Genomic characterization findings of 72 ARV field isolates obtained from broiler cases during the last 6 years indicated that six distinct cluster variant strains (genotype I-VI), which were genetically diverse and distant from the vaccine and vaccine-related field strains, continuously circulated in PA poultry. Most of the variants clustered within genotype V (24/72, 33.3%), followed by genotype II (16/72, 22.2%), genotype IV (13/72, 18.1%), genotype III (13/72, 18.1%), genotype VI (05/72, 6.94%), and genotype I (1/72, 1.38%). The amino acid identity between 72 field variants and the vaccine strains (1133, 1733, 2408, 2177) varied from 45.3% to 99.7%, while the difference in amino acid counts ranged from 1–164. Among the field variants, the amino acid identity and count difference ranged from 43.3% to 100% and 0 to 170, respectively. Variants within genotype V had maximum amino acid identity (94.7–100%), whereas none of the variants within genotypes II and VI were alike. These findings indicate the continuing occurrence of multiple ARV genotypes in the environment.

41 Is there anything we can do to lessen the severity of PRRSv?

Abstract Veterinarians and the swine industry continue to battle PRRS virus (v), as demonstrated by both the MSHMP (Morrison Swine Health Monitoring Project) and the SDRS (Swine Disease Reporting System). Both systems depict a continued increase in PRRSv prevalence and percentage of positive cases. The PRRSv variants that are circulating today seem to be more severe, especially in the last 2 to 3 yr, with more significant health and production losses in the nursery and finishing phases for prolonged periods of time. The best thing that can be done is to avoid having the virus with a good bioexclusion plan and if sites become infected, a strong biocontainment plan to avoid contaminating more sites should be considered. Realizing that bioexclusion is not always possible and sites will become infected, there are methods to help to reduce the impact of the virus. With the concerns of recombination pushing the virus evolution along faster, more producers are working toward eliminating field viruses from their systems. The use of filtration both on sow farms and nurseries has become more common as well as an additional method of bioexclusion. In the face of an outbreak, obtaining an accurate diagnosis is still one of the most important things that we do. In farrow to wean farms, serum samples are generally used when clinical signs (e.g., abortions, off feed) are observed to target testing to specific animals that are more likely to allow for early detection. In nursery and finishing sites, the use of oral fluid has worked very well as a screening tool when there are clinical signs or problems within a group or flow. Fortunately, there are differential tests that can be used to identify field infection and vaccines strains (since most wean to finish pigs are vaccinated in pig dense areas). With severe strains, depopulation and repopulation strategies have become more popular as a control method, but the majority of herd would use a herd closure. However, the amount of time required for these closures is extending, which lengthens the impacts on sow farms. Among wean to finish systems, the use of depopulating and cleaning up the site is used most, with only routine down times. Anti-inflammatories can also be administered in the acute phase of the outbreak in addition to the use of antibiotics to control secondary bacterial infections, as well as providing a good environment to allow the pigs to better deal with the disease. It’s best to keep the virus out of the herd with a good bioexclusion program. However, when we do have outbreaks, anti-inflammatory and antibiotics to help the pigs through it are important to utilize as we work to eliminate the field virus from the herd.

An intranasal nanoparticle vaccine elicits protective immunity against Mycobacterium tuberculosis

Mucosal vaccines have the potential to elicit protective immune responses at the point of entry of respiratory pathogens, thus preventing even the initial seed infection. Unlike licensed injectable vaccines, mucosal vaccines comprising protein subunits are only in development. One of the primary challenges associated with mucosal vaccines has been identifying and characterizing safe yet effective mucosal adjuvants that can effectively prime multi-factorial mucosal immunity. In this study, we tested NanoSTING, a liposomal formulation of the endogenous activator of the stimulator of interferon genes (STING) pathway, cyclic guanosine adenosine monophosphate (cGAMP), as a mucosal adjuvant. We formulated a vaccine based on the H1 antigen (fusion protein of Ag85b and ESAT-6) adjuvanted with NanoSTING. Intranasal immunization of NanoSTING-H1 elicited a strong T-cell response in the lung of vaccinated animals characterized by (a) CXCR3+ KLRG1− lung resident T cells that are known to be essential for controlling bacterial infection, (b) IFNγ-secreting CD4+ T cells which is necessary for intracellular bactericidal activity, and (c) IL17-secreting CD4+ T cells that can confer protective immunity against multiple clinically relevant strains of Mtb. Upon challenge with aerosolized Mycobacterium tuberculosis Erdman strain, intranasal NanoSTING-H1 provides protection comparable to subcutaneous administration of the live attenuated Mycobacterium bovis vaccine strain Bacille–Calmette–Guérin (BCG). Our results indicate that NanoSTING adjuvanted protein vaccines can elicit a multi-factorial immune response that protects from infection by M. tuberculosis.

Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination.

The assessment of long-term humoral and cellular immunity post-vaccination is crucial for establishing an optimal vaccination strategy. This prospective cohort study evaluated adults (≥18 years) who received a BA.4/5 bivalent vaccine. We measured the anti-receptor binding domain immunoglobulin G antibody and neutralizing antibodies (NAb) against wild-type and Omicron subvariants (BA.5, BQ.1.1, BN.1, XBB.1 and EG.5) up to 9 months post-vaccination. T-cell immune responses were measured before and 4 weeks after vaccination. A total of 108 (28 SARS-CoV-2-naïve and 80 previously infected) participants were enrolled. Anti-receptor binding domain immunoglobulin G (U/mL) levels were higher at 9 months post-vaccination than baseline in SAR-CoV-2-naïve individuals (8,339 vs. 1,834, p<0.001). NAb titers against BQ.1.1, BN.1, and XBB.1 were significantly higher at 9 months post-vaccination than baseline in both groups, whereas NAb against EG.5 was negligible at all time points. The T-cell immune response (median spot forming unit/106 cells) was highly cross-reactive at both baseline (wild-type/BA.5/XBB.1.5, 38.3/52.5/45.0 in SARS-CoV-2-naïve individuals; 51.6/54.9/54.9 in SARS-CoV-2-infected individuals) and 4 weeks post-vaccination, with insignificant boosting post-vaccination. Remarkable cross-reactive neutralization was observed against BQ.1.1, BN.1, and XBB.1 up to 9 months after BA.4/5 bivalent vaccination, but not against EG.5. The T-cell immune response was highly cross-reactive.

Combination of S1-N-Terminal and S1-C-Terminal Domain Antigens Targeting Double Receptor-Binding Domains Bolsters Protective Immunity of a Nanoparticle Vaccine against Porcine Epidemic Diarrhea Virus.

Variants of coronavirus porcine epidemic diarrhea virus (PEDV) frequently emerge, causing an incomplete match between the vaccine and variant strains, which affects vaccine efficacy. Designing vaccines with rapidly replaceable antigens and high efficacy is a promising strategy for the prevention of infection with PEDV variant strains. In our study, three different types of self-assembled nanoparticles (nps) targeting receptor-binding N-terminal domain (NTD) and C-terminal domain (CTD) of S1 protein, named NTDnps, CTDnps, and NTD/CTDnps, were constructed and evaluated as vaccine candidates against PEDV. NTDnps and CTDnps vaccines mediated significantly higher neutralizing antibody (NAb) titers than NTD and CTD recombinant proteins in mice. The NTD/CTDnps in varying ratios elicited significantly higher NAb titers when compared with NTDnps and CTDnps alone. The NTD/CTDnps (3:1) elicited NAb with titers up to 92.92% of those induced by the commercial vaccine. Piglets immunized with NTD/CTDnps (3:1) achieved a passive immune protection rate of 83.33% of that induced by the commercial vaccine. NTD/CTDnps (3:1) enhanced the capacity of mononuclear macrophages and dendritic cells to take up and present antigens by activating major histocompatibility complex I and II molecules to stimulate humoral and cellular immunity. These data reveal that a combination of S1-NTD and S1-CTD antigens targeting double receptor-binding domains strengthens the protective immunity of nanoparticle vaccines against PEDV. Our findings will provide a promising vaccine candidate against PEDV.

Molecular Detection and Characterization of Newcastle Disease Virus from Chickens in Mid-Rift Valley and Central Part of Ethiopia.

Newcastle disease (ND) is a highly infectious poultry disease that causes major economic losses worldwide. The disease is caused by Newcastle Disease Virus (NDV) and early detection and identification of the viral strain is essential. Having knowledge of the NDV strain genotype that circulates in some regions would help in designing an effective vaccine to control the disease. In this regard, there is little information on NDV strain in chickens in mid Rift Valley and the central part of Ethiopia. Therefore, the purpose of this study was to detect and characterize NDV strain genotype from chickens in mid-Rift Valley and the central part of Ethiopia and test whether this NDV strain genotype matches the vaccine strain currently used in the study area. A total of 98 samples: 78 (tracheal and cloacal) swabs from chicken pools of five and 20 tissue samples were collected. To detect NDV strain, conserved region of the virus Matrix (M) gene was amplified by qRT-PCR. To characterize NDV strain genotypes, M-gene positive samples were specifically re-amplified by conventional PCR targeting the Fusion (F) gene region and sequenced by Sanger method. 13.26% of tested samples were positive for NDV strain in the study area with statistically significant difference (P<0.05) among the study sites. Further characterization of the F genes from NDV strain isolates by phylogenetic analysis indicated that one field isolate clustered with genotype VII whereas three of the isolates clustered to genotype I, II, and III. The isolate of the current NDV strain vaccine in use in the study area clustered with genotype II. The current study indicates the existence of different NDV strain genotype from that of the vaccine strain currently used. Even though large-scale characterization of several isolates is required at national level, the current study laid baseline information for the existence of variations between field NDV strain genotype and vaccine strain currently used against ND in the country.

Prime-boost vaccination combining rF1-V subunit and novel live attenuated bacterial strains protects mice from virulent aerosolized nonencapsulated Yersinia pestis

Abstract Yersinia pestis (Yp) is a security concern since it can be aerosolized and cause pneumonic plague, a rapidly progressing illness that is fatal if not treated promptly with antibiotics. There are no FDA-approved vaccines, and candidate vaccines are less effective against pneumonic than bubonic plague. The major protective vaccine antigen has been the F1 capsule protein; protection against nonencapsulated strains has been elusive. We constructed two novel live attenuated vaccine (LAV) strains on the pgm-pPst- background, which is excluded from the CDC select agent list due to established safety. These strains, Δcaf1 and ΔyopD/Δcaf1, lack F1 and may be more effective at inducing immunity against nonencapsulated strains like C12. Female BALB/c mice were immunized with a heterologous prime-boost strategy combining one subcutaneous injection of novel LAV and one of recombinant F1-V (rF1-V) subunit, then challenged with aerosolized virulent Yp C12 and monitored for survival, bacterial load, and immunological factors. Priming with rF1-V and boosting with LAV was more protective than the reverse strategy. Protection was accompanied by high antibody titers against rF1-V and rV. rF1-V prime and LAV boost also led to a higher IgG2a/IgG1 antibody ratio than the reverse, suggesting a balanced Th1/Th2 response. These data support rF1-V prime and pgm-pPst-Δcaf1 LAV boost as a promising strategy for a safe and effective vaccine against both encapsulated and nonencapsulated Yp.

Isolation and molecular characterization of very virulent infectious bursal disease virus from Egypt

In Egypt, the poultry industry is plagued by the significant economic losses caused by the infectious bursal disease virus (IBDV). In the present study, a total of 30 diseased commercial chicken flocks aged 23–41 days old in three Egyptian governorates (Fayoum, Beni-Suef, and Minya) having symptoms consistent with IBDV were examined. The collected bursal samples (n=30, ten pooled bursae for each flock) were screened by RT-PCR to amplify the IBDV VP2 gene. Results revealed that 20 out of 30 samples were positive, as indicated by the amplification of 620 bp of the VP2 gene. The twenty positive samples were inoculated into specific pathogen-free embryonated chicken eggs (SPF-ECEs) via the chorioallantoic-membrane (CAM) route to isolate the suspected virus. Eight samples were successfully isolated and were subjected to a partial sequence of VP2 (targeting the HVR). The nucleotide sequences and phylogenetic analysis revealed that the examined isolates exhibited amino acids A222, I256, I294, and S299, which are extremely conserved among very virulent (vv)IBDV. The amino acid sequence analysis of the eight isolates revealed a high degree of similarity (97-100%) in between and 90-100% similarity compared to other Egyptian vvIBDV strains. In contrast, lower similarity was observed with attenuated IBDV vaccine strains D78, Lukert, and Bursavac (91-93%, 91-93%, and 92-94%, respectively). In conclusion, this study underscores the importance of ongoing surveillance of the IBDV situation in the field, as well as the need for further research to investigate the efficacy of current vaccination strategies to curb IBDV infection.

Treatment considerations for bluetongue virus serotype‐3 cases in sheep

Background: Bluetongue virus (BTV) serotype‐3 (BTV‐3) has been circulating in the Netherlands since September 2023 and was first reported in Kent in the UK in November 2023, picked up via the annual bluetongue surveillance programme. It is a highly pathogenic strain in sheep with limited preventive measures once virus is circulating in the biting midge population. At the time of publication there is no BTV‐3 vaccine available and no cross‐protection from other BTV vaccine strains. There are no specific antiviral medicines available, and therapy focuses on nursing care and anti‐inflammatory medicines to reduce clinical signs, although early euthanasia decisions need to be considered on the grounds of animal welfare.Aim of the article: This article takes the experiences of vets from the Netherlands and describes what practitioners might be able to do to treat clinical cases of BTV‐3, with thanks to Schapendokter (2023) for sharing their practice protocols.

Evaluation of Swine Protection with Three Commercial Foot-and-Mouth Disease Vaccines against Heterologous Challenge with Type A ASIA/G-VII Lineage Viruses.

Outbreaks caused by foot-and-mouth disease (FMD) A/ASIA/G-VII lineage viruses have often occurred in Middle Eastern and Southeast Asian countries since 2015. Because A/ASIA/G-VII lineage viruses are reported to have distinct antigenic relatedness with available commercial FMD vaccine strains, it is necessary to investigate whether inoculation with vaccines used in Korea could confer cross-protection against A/ASIA/G-VII lineage viruses. In the present study, we conducted two vaccination challenge trials to evaluate the efficacy of three commercial FMD vaccines (O/Manisa + O/3039 + A/Iraq, O/Campos + A/Cruzeiro + A/2001, and O/Primorsky + A/Zabaikalsky) against heterologous challenge with ASIA/G-VII lineage viruses (A/TUR/13/2017 or A/BHU/3/2017 strains) in pigs. In each trial, clinical signs, viremia, and salivary shedding of virus were measured for 7 days after challenge. In summary, the O/Campos + A/Cruzeiro + A/2001 vaccine provided full protection against two A/ASIA/G-VII lineage viruses in vaccinated pigs, where significant protection was observed. Although unprotected animals were observed in groups vaccinated with O/Manisa + O/3039 + A/Iraq or O/Primorsky + A/Zabaikalsky vaccines, the clinical scores and viral RNA levels in the sera and oral swabs of vaccinated animals were significantly lower than those of unvaccinated controls.

Nanopore sequencing of influenza A and B in Oxfordshire and the United Kingdom, 2022–23

We evaluated Nanopore sequencing for influenza surveillance. Influenza A and B PCR-positive samples from hospital patients in Oxfordshire, UK, and a UK-wide population survey from winter 2022-23 underwent Nanopore sequencing following targeted rt-PCR amplification. From 941 infections, successful sequencing was achieved in 292/388(75%) available Oxfordshire samples: 231(79%) A/H3N2, 53(18%) A/H1N1, and 8(3%) B/Victoria and in 53/113(47%) UK-wide samples. Sequencing was more successful at lower Ct values. Most same-sample replicate sequences had identical haemagglutinin segments (124/141, 88%); 36/39(92%) Illumina vs. Nanopore comparisons were identical, and 3(8%) differed by 1 variant. Comparison of Oxfordshire and UK-wide sequences showed frequent inter-regional transmission. Infections were closely-related to 2022-23 vaccine strains. Only one sample had a neuraminidase inhibitor resistance mutation. 849/941(90%) Oxfordshire infections were community-acquired. 63/88(72%) potentially healthcare-associated cases shared a hospital ward with ≥1 known infectious case. 33 epidemiologically-plausible transmission links had sequencing data for both source and recipient: 8 were within ≤5 SNPs, of these, 5(63%) involved potential sources that were also hospital-acquired. Nanopore influenza sequencing was reproducible and antiviral resistance rare. Inter-regional transmission was common; most infections were genomically similar. Hospital-acquired infections are likely an important source of nosocomial transmission and should be prioritised for infection prevention and control.

Developing a Nano Platform for Bovine Brucellosis Diagnostic Product

Background: Brucellosis is one of the most common zoonoses caused by Brucella species. Brucella is an intracellular pathogen that causes abortion in domestic animals and brucellosis in humans. The disease has no specific pathognomonic signs; hence a prompt and accurate diagnosis of the disease plays a very critical role in preventing brucella transmission and treating the disease.Methods: Research was carried out at the Department of Veterinary Science of Kazakh National Agrarian Research University and in the Molecular Biology laboratory of the Institute for Plant Biology and Biotechnology under the Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan. Studies were carried out on a killed culture of the vaccine strain Brucella abortus RB19, genomic DNA of B. abortus RB19, Grapevine virus A, plasmid vectors for DNA cloning, a fluorescent nano marker, and Brucella membrane proteins.Results: The research demonstrated that brucellosis remained one of the most common zoonotic diseases worldwide. This disease not only resulted in significant economic losses in agriculture but also posed a serious threat to public health.Conclusions: The study successfully established prokaryotic expression vectors for efficient protein production, validated through sequencing and Western blotting, and proposed a promising nano-platform for plant-based synthesis of brucellosis proteins, with potential implications for diagnostic kit development and vaccine research in agriculture.Keywords: Brucellosis; Brucella; Outer membrane proteins; Omp16

A Review on the Methodology and Use of the Pregnant Mouse Model in the Study of Brucella Reproductive Pathogenesis and Its Abortifacient Effect.

Brucellosis is one of the most common and widespread bacterial zoonoses and is caused by Gram-negative bacteria belonging to the genus Brucella. These organisms are able to infect and replicate within the placenta, resulting in abortion, one of the main clinical signs of brucellosis. Although the mouse model is widely used to study Brucella virulence and, more recently, to evaluate the protection of new vaccines, there is no clear consensus on the experimental conditions (e.g., mouse strains, doses, routes of inoculation, infection/pregnancy time) and the natural host reproducibility of the pregnant mouse model for reproductive brucellosis. This lack of consensus calls for a review that integrates the major findings regarding the effect of Brucella wild-type and vaccine strains infections on mouse pregnancy. We found sufficient evidence on the utility of the pregnant mouse model to study Brucella-induced placentitis and abortion and propose suitable experimental conditions (dose, time of infection) and pregnancy outcome readouts for B. abortus and B. melitensis studies. Finally, we discuss the utility and limitations of the pregnant mouse as a predictive model for the abortifacient effect of live Brucella vaccines.

Evaluation Of Infectious Bursal Disease Virus Maternally Derived Antibody Decay Rate In Day Old Broilers From Different Hatcheries In Nigeria

Infectious Bursal disease (IBD) is an immunosuppressive disease of young chicks, which is responsible for major economic losses in the poultry industry worldwide, particularly for the last decades. This study utilized a cross-sectional approach to evaluate Infectious bursal disease virus (IBDV) maternally derived antibody decay rate in day old chicks (D.O.C) obtained from different hatcheries in Nigeria. Of the 450 serum samples collected through random selection with replacement method, (i.e 90 samples from the 5 hatcheries designated as farms A – E), it was observed that farm A at day 1 had mean Elisa titre of (4213 ± 366.66), farm B (2178.225 ± 292.477), farm C (1629.699 ± 229.2197), farm D (3452.609 ± 403.64.6469) and farm E (1651.789 ± 201.6811), these values were far above the protective (positive) level of 875, recommended by IDvet manual with (S/P ratios of 0.350). This level was maintained, although, with minimal decays, up to day 7 for farms A, D and E but farm B and C did not exceed day 6 and day 5 respectively. Only farm D presented protective (positive) value that lasted to day 13. The best fit for this decay rate was calculated to be Y = -2263In(x) + 3714 (week) with R2 = (0.903). From these studies we could deduce that these farms were truly vaccinated or immunized as expected and they presented different antibody titres with variable decay rates. It would have been a good idea to recommend that same vaccination schedule should not be applied indiscriminately to broilers from these farms like other researchers have, but this would rather be to the detriment of many farmers who may not be privileged to access the detailed information on which schedule is meant for which farm .We therefor recommend that broilers from these hatcheries be vaccinated between day 7 to day 10 post hatch and a booster dose (if necessary) should be administered a week after, with an intermediate plus strain vaccine type that has the capacity to penetrate through the MDA and induce humoral-immunity-in- thechicks.

Study of a lytic bacteriophage as a tool for the control of Salmonella Gallinarum in layer poultry

One of the leading diseases affecting laying poultry in Argentina is fowl typhoid, caused by the pathogen Salmonella enterica serovar Gallinarum (S. Gallinarum). Although this disease was eradicated from industrial hatcheries in several developed countries, it is still present in commercial farms in Latin America, causing substantial economic losses due to high mortality rates, limited production of quality eggs, high veterinary costs, and the need to renovate infected facilities. To develop a new S. Gallinarum biocontrol method, in the present study, we characterized a bacteriophage in terms of host specificity, growth kinetics, and stability under different environmental conditions. The phage could infect an ample range of bacterial hosts and had no lytic activity against the vaccine strain 9R. Moreover, the phage was stable at pH 3, chloroform presence did not significantly reduce its titer, and its activity wasnot affected by antibiotics or various chemical agents often used in aviculture. Application of a phage suspension on S. Gallinarum-contaminated surfaces resulted in a significant reduction of bacterial load (p &lt; 0.05). These results show that lytic bacteriophages such as the one studied here are innovative alternatives with potential applications to control S. Gallinarum in laying poultry farms.

Molecular characterization and phylogenetic analysis of porcine epidemic diarrhea virus in Xinjiang, China, from 2020 to 2022.

In recent years, the pig industry in Xinjiang, China, has been severely impacted by outbreaks of porcine epidemic diarrhea (PED), despite vaccination efforts. In this study, we investigated the genetic characteristics of currently prevalent porcine epidemic diarrhea virus (PEDV) strains in the region. We collected 548 samples from animals with suspected PED on large-scale pig farms in Xinjiang. Of these, 258 tested positive for PEDV by RT-PCR, yielding an overall positivity rate of 47.08%. S1 gene sequencing and phylogenetic analysis were conducted on 23 randomly selected RT-PCR-positive samples. Three endemic strains of PEDV (PEDV/CH/XU/2020, PEDV/CH/XK/2020, and PEDV/CH/XA/2020) were isolated, and their complete genome sequences were analyzed for evidence of genetic recombination. Sequence comparison of the S gene indicated significant variations in the S1 gene of the Xinjiang strains compared to the vaccine strains CV777, AJ1102, and LWL, with 90.2%-98.5% nucleotide sequence identity. Notably, both the N-terminal and C-terminal domains of the S protein showed significant variation. Genetic evolutionary analysis identified the GIIa subtype as the dominant genotype among the epidemic strains in Xinjiang. Recombination analysis revealed inter-subtype recombination events in the PEDV/CH/XK/2020 and XJ1904-34 strains. These findings highlight the extensive genetic variation in the predominant GIIa genotype of PEDV in Xinjiang, which does not match the genotype of the currently used vaccine strains. These data may guide further efforts toward the development of effective vaccines for the control of PED.

A live attenuated Salmonella Typhimurium vaccine dose and diluent have minimal effects on the caecal microbiota of layer chickens.

Among the Salmonella reduction strategies in poultry production, one option is to use a Salmonella vaccine. The aim of vaccinating layer flocks is to reduce the shedding of wild-type Salmonella in the poultry environment, thereby reducing the contamination of poultry products (eggs and meat). Nutritive diluent and a higher dose of vaccine may enhance its colonization potential in the gut of chickens. In this study, a commercially available live attenuated vaccine (Vaxsafe® ST) was reconstituted in different media and delivered orally to day-old chicks at three different doses (107, 108, and 109 CFU/chick). Gut colonization of the vaccine strain and the effects of vaccination on gut microbiota were assessed in commercial-layer chickens. The vaccine diluent and dosage minimally affected microbiota alpha diversity. Microbiota beta diversity was significantly different (P < 0.05) based on the vaccine diluent and dose, which indicated that the vaccinated and unvaccinated chickens had different gut microbial communities. Differences were noted in the abundance of several genera, including Blautia, Colidextribacter, Dickeya, Enterococcus, Lactobacillus, Pediococcus, and Sellimonas. The abundance of Colidextribacter was significantly lower in chickens that received vaccine reconstituted in Marek's and water diluents, while Lactobacillus abundance was significantly lower in the water group. The highest vaccine dose (109 CFU/chick) did not significantly alter (P > 0.05) the abundance of microbial genera. Chicken age affected the microbiota composition more significantly than the vaccine dose and diluent. The abundance of Lactobacillus, Blautia, Caproiciproducens, Pediococcus, and Colidextribacter was significantly higher on day 14 compared with day 7 post-vaccination. The Salmonella Typhimurium vaccine load in the caeca was not significantly affected by diluent and vaccine dose; however, it was significantly lower (P < 0.0001) on day 14 compared with day 7 post-vaccination. Overall, the S. Typhimurium vaccine minimally affected the gut microbiota structure of layer chicks, whereas changes in microbiota were more significant with chicken age.

Recombinant Vaccine Strain ASFV-G-Δ9GL/ΔUK Produced in the IPKM Cell Line Is Genetically Stable and Efficacious in Inducing Protection in Pigs Challenged with the Virulent African Swine Fever Virus Field Isolate Georgia 2010.

We have previously reported that the recombinant African Swine Fever (ASF) vaccine candidate ASFV-G-Δ9GL/ΔUK efficiently induces protection in domestic pigs challenged with the virulent strain Georgia 2010 (ASFV-G). As reported, ASFV-G-Δ9GL/ΔUK induces protection, while intramuscularly (IM), administered at doses of 104 HAD50 or higher, prevents ASF clinical disease in animals infected with the homologous ASFV g strain. Like other recombinant vaccine candidates obtained from ASFV field isolates, ASFV-G-Δ9GL/ΔUK stocks need to be produced in primary cultures of swine macrophages, which constitutes an important limitation in the production of large virus stocks at the industrial level. Here, we describe the development of ASFV-G-Δ9GL/ΔUK stocks using IPKM (Immortalized Porcine Kidney Macrophage) cells, which are derived from swine macrophages. We show that ten successive passages of ASFV-G-Δ9GL/ΔUK in IPKM cells induced small changes in the virus genome. The produced virus, ASFV-G-Δ9GL/ΔUKp10, presented a similar level of replication in swine macrophages cultures to that of the original ASFV-G-Δ9GL/ΔUK (ASFV-G-Δ9GL/ΔUKp0). The protective efficacy of ASFV-G-Δ9GL/ΔUKp10 was evaluated in pigs that were IM-inoculated with either 104 or 106 HAD50 of ASFV-G-Δ9GL/ΔUKp10. While animals inoculated with 104 HAD50 present a partial protection against the experimental infection with the virulent parental virus ASFV-G, those inoculated with 106 HAD50 were completely protected. Therefore, as was just recently reported for another ASF vaccine candidate, ASFV-G-ΔI177L, IPKM cells are an effective alternative to produce stocks for vaccine strains which only grow in swine macrophages.

Potential Pathogenicity and Genetic Characteristics of a Live-Attenuated Classical Swine Fever Virus Vaccine Derivative Variant

Classical swine fever (CSF), caused by CSF virus (CSFV), is a highly contagious disease affecting pigs and causing massive pig production losses with severe global economic recession. The immunization of live-attenuated vaccines is still one of the key measures to CSFV management in endemic countries. However, there are also strong controversies about the usage of live-attenuated vaccines, particularly in pregnant sows and young pigs, such as in Europe, where domestic pigs are routinely not vaccinated until severe outbreaks occur. Here, we report a CSF outbreak in a pig farm in China, which affected more than 90% of the delivery sows and led to ∼45% birth loss. Surprisingly, phylogenetic analysis showed that the CSFV isolate (named CSFV/HeNLY2022, GenBank No. OR195698) was clustered into subgenotype 1.1a, closely together with the live-attenuated vaccine strains. Further genomic analysis also revealed that the isolate CSFV/HeNLY2022 shared the highest nucleotide identity of 99.7% with the C/HVRI vaccine strain (C-strain, GenBank No. AY805221). Moreover, compared to the C/HVRI strain, a total of eight amino acid mutations, distributed in Erns (H436thY and S476thR), E1 (T502thI and P581thT), E2 (M979thK and A1061thS), NS5A (A2980thT), and NS5B (I3818thM), were characterized in the CSFV/HeNLY2022 isolate. Our results suggested that the CSF outbreak was most likely caused by the live-attenuated CSFV vaccine or its derivative. It raises concern that the unscientific application of CSFV vaccines could potentially lead to CSFV spread in pigs. It is needed to perform a more rigorous evaluation of the safety of the C-strain-derived vaccines in combination with other different live-attenuated vaccines.